TIDMORPH

Open Orphan PLC

15 November 2019

15th November 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Open Orphan to attend Jefferies 2019 London Healthcare Conference

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20(th) -21(st) November 2019 in London, UK.

The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare.

Open Orphan's Chief Executive Officer, Cathal Friel, will be in attendance and will be doing one-on-one meetings with attendees at the conference.

Enquiries:

Open Orphan Plc Tel: +353 (0)1 6440007

Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363

Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAGGGRPGUPBGMC

(END) Dow Jones Newswires

November 15, 2019 02:00 ET (07:00 GMT)

Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Venn Life Sciences
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Venn Life Sciences